Ramon Santos Olivera, MD
Family Medicine · Fishers, INNPI 1053867309
Payments from drug & device makers
Across 174 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$590
- Bayer$407
- Lilly USA, LLC$381
- Pfizer$289
- AbbVie$208
- AstraZeneca$202
- plus $981 from 22 others
What the payments were for
- Food & beverage$3,057100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $590 |
| Bayer | 25 | $407 |
| Lilly USA, LLC | 19 | $381 |
| Pfizer | 19 | $289 |
| AbbVie | 15 | $208 |
| AstraZeneca | 8 | $202 |
| Amgen | 7 | $130 |
| Boehringer Ingelheim | 6 | $105 |
| Abbott | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Shield Therapeutics Inc | 2 | $57 |
| Johnson & Johnson | 3 | $56 |
| Exact Sciences | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Corium, LLC | 2 | $41 |
| Merck | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Antares Pharma, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Almatica Pharma LLC | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| GSK | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,057 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 302 | $118,651 |
| RybelsusSemaglutide | 37 | $71,340 |
| TrulicityDulaglutide | 43 | $65,854 |
| JardianceEmpagliflozin | 77 | $54,151 |
| OzempicSemaglutide | 20 | $40,846 |
| Nurtec OdtRimegepant Sulfate | 30 | $35,526 |
| JanuviaSitagliptin Phosphate | 56 | $34,132 |
| MounjaroTirzepatide | 29 | $30,014 |
| LinzessLinaclotide | 22 | $19,275 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $17,619 |
| XareltoRivaroxaban | 31 | $15,286 |
| FarxigaDapagliflozin Propanediol | 31 | $15,033 |
| EntrestoSacubitril/Valsartan | 29 | $14,440 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $12,156 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $289 | $154,177332 claims |
| Novo NordiskRybelsus, Ozempic | $590 | $112,18657 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $381 | $95,86772 claims |
| Boehringer IngelheimJardiance | $105 | $54,15177 claims |
| MerckJanuvia, Janumet, Janumet Xr | $39 | $54,10381 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $12 | $34,33575 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $202 | $29,05361 claims |
| AbbVieLinzess | $208 | $19,27522 claims |
| Johnson & JohnsonXarelto | $56 | $15,28631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fishers
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.